Lancet Oncol: immunotherapy drugs provide new treatment opportunities for patients who have previously received treatment for renal cancer and lung cancer

October 23, 2019 / Biovalley BIOON / -- pegilodecakin is a kind of drug currently undergoing clinical trials, which has shown positive safety results, and may provide a potential new treatment approach for non-small cell lung cancer (NSCLC) and renal cancer patients A study led by the MD Anderson Cancer Center at the University of Texas showed that the drug, in combination with two major anti-PD-1 monoclonal antibodies, pembrolizumab and nivolumab, produced measurable responses in these patients The results of this multicenter IB phase study were recently published in Lancet Oncology Photo source: https://cn.bing.com "the combination of anti-PD-1 monoclonal antibody and pegilodecakin has controllable toxicity and promising anti-tumor activity "Said Dr Aung Naing, associate professor "Our study showed that this combination showed a good response in patients with NSCLC and renal cancer who had previously been treated compared to patients treated with anti-PD-1 monoclonal antibodies alone "The purpose of this study was to assess the safety, tolerability and maximum tolerable dose of pegilodecakin in combination with pembrolizumab or nivolumab, and to study biomarkers to identify patients who may respond to treatment The study, conducted from February 2015 to September 2017, tracked 111 patients with renal cancer, non-small cell lung cancer, and advanced malignant solid tumor melanoma The most common side effects are anemia, fatigue, low platelet count and high triglyceride levels The results showed that 43% of NSCLC patients, 40% of renal cancer patients and 10% of melanoma patients had objective reactions The patients were treated with pegilodecakin in combination with pembrolizumab or nivolumab until the disease progressed, the toxicity needed to be stopped, the patients withdrew their consent or the study ended If the investigator determines that the patient will continue to benefit, the patient will continue to receive combination therapy or pegilodecakin alone after the disease progresses Pegilodecakin is formed by recombinant interleukin-10 (IL-10) coupled with polyethylene glycol (PEG) IL-10 is a kind of protein that regulates the activity of many immune cells High concentration of IL-10 can activate the immune response to cancer cells The combination of PEG and IL-10 increased its volume, prevented or delayed its decomposition, and prolonged its circulation time in vivo The drug works by stimulating the survival, proliferation and "killing" potential of CD8 + T cells, known for their ability to recognize and destroy cancer cells It is generally believed that increasing the number of CD8 + T cells in tumor can improve the prognosis and survival of patients The immunostimulatory effect of pegilodecakin complements the effect of anti-PD-1 monoclonal antibody on T cell immunosuppression "Pegilodecakin combines the activity of anti-PD-1 monoclonal antibodies to introduce a new class of drugs for the treatment of advanced solid tumors," Naing said Future randomized trials are expected to determine the tolerance and clinical benefits of pegilodecakin as a single drug and as a combination in a range of cancer treatments "Reference: Aung Naing et al Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (Ivy): a multicenter, multicohort, open label, phase 1b trial The Lancet Oncology, 2019 doi: 10.1016/s1470-2045 (19) 30514-5